Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 792 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $146.04, for a total transaction of $115,663.68. Following the transaction, the chief financial officer now directly owns 71,869 shares of the company's stock, valued at $10,495,748.76. The trade was a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, February 3rd, Michael Burkes Brophy sold 43,502 shares of Natera stock. The shares were sold at an average price of $176.88, for a total transaction of $7,694,633.76.
- On Wednesday, January 29th, Michael Burkes Brophy sold 4,335 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $719,046.45.
- On Friday, January 31st, Michael Burkes Brophy sold 1,886 shares of Natera stock. The shares were sold at an average price of $176.60, for a total transaction of $333,067.60.
- On Monday, January 27th, Michael Burkes Brophy sold 1,442 shares of Natera stock. The shares were sold at an average price of $161.87, for a total transaction of $233,416.54.
- On Friday, January 24th, Michael Burkes Brophy sold 946 shares of Natera stock. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08.
- On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07.
Natera Trading Up 3.1 %
NTRA stock opened at $150.87 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company has a market capitalization of $20.40 billion, a PE ratio of -85.72 and a beta of 1.80. The firm's 50-day moving average is $162.25 and its 200 day moving average is $149.27. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00.
Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Principal Securities Inc. increased its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares during the period. Gladstone Institutional Advisory LLC grew its position in shares of Natera by 1.7% in the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock worth $574,000 after buying an additional 61 shares during the last quarter. Silver Oak Securities Incorporated grew its position in shares of Natera by 3.1% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after buying an additional 89 shares during the last quarter. Colonial Trust Co SC grew its position in shares of Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after buying an additional 96 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after buying an additional 97 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.
Analyst Ratings Changes
Several equities analysts have commented on NTRA shares. Canaccord Genuity Group reiterated a "buy" rating and set a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Sanford C. Bernstein raised their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, January 10th. Piper Sandler raised their target price on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. JPMorgan Chase & Co. raised their target price on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. Finally, The Goldman Sachs Group raised their target price on shares of Natera from $160.00 to $190.00 and gave the stock a "buy" rating in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $178.12.
Get Our Latest Stock Report on Natera
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
